{"entity":{"id":"nct06534437","kind":"trial","name":"MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)","aka":[],"tldr":"A phase 2 trial of MEN1703, Glofitamab in hodgkin lymphoma and non-hodgkin lymphoma, run by Ryvu Therapeutics SA, now recruiting.","summary":"MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01) is a phase 2 interventional study registered as NCT06534437 by Ryvu Therapeutics SA, with 178 participants planned, started 2024-12-05 and due to reach its primary completion in 2026-12. Interventions recorded: MEN1703, Glofitamab. Conditions listed: Non-Hodgkin Lymphoma, B-cell. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06534437","url":"https://clinicaltrials.gov/study/NCT06534437"}],"tags":["ctgov-ingest"],"related":[],"cancers":["hodgkin-lymphoma","non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["men1703","glofitamab"],"companies":["ryvu-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06534437","phase":"2","setting":"An Open Label, Phase 2 Clinical Trial of MEN1703 as Monotherapy and in Combination With Glofitamab in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma","sponsor":"Ryvu Therapeutics SA","enrolled":178,"outcomes":[]},"route":"/trials/nct06534437/","neighbours":{"cancer":[{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"drug":[{"id":"glofitamab","kind":"drug","name":"Glofitamab","route":"/drugs/glofitamab/"},{"id":"men1703","kind":"drug","name":"MEN1703","route":"/drugs/men1703/"}],"company":[{"id":"ryvu-therapeutics","kind":"company","name":"Ryvu Therapeutics","route":"/companies/ryvu-therapeutics/"}]}}